Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic
25-02-2021
Actavis and Teva sued over narcotic addiction generic
01-03-2017
madamF / Shutterstock.com
The US Court of Appeals for the Federal Circuit has affirmed US Patent Trial and Appeal Board’s (PTAB) decisions upholding three patents related to Teva Pharmaceutical’s migraine drug Ajovy, but has invalidated six others.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
US Court of Appeals for the Federal Circuit, PTAB, Alan Lourie, William Bryson and Kathleen O’Malley, Teva Pharmaceutical, McKool Smith
